DKP
BIOS

Davidson Kempner Partners’s BioPlus Acquisition Corp. Class A Ordinary Shares BIOS Stock Holding History

Davidson Kempner Partners’s Portfolio BIOS Stock Details BIOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$2.61M Buy
+250,000
New +$2.59M 0.05% 190

Other funds holding BIOS

AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
PMAM
Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.48% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Davidson Kempner Partners's BIOS Position: Q1 2023 in Review

Davidson Kempner Partners opened a new position in BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) in Q1 2023: 250,000 shares worth $2.61M. The stake represents 0.05% of the portfolio and ranks #190 among its holdings.

61 funds tracked by Wall St. Rank hold BIOS as of Q1 2023.

  • Davidson Kempner Partners held 250,000 shares of BioPlus Acquisition Corp. Class A Ordinary Shares worth $2.61M as of Q1 2023.
  • BioPlus Acquisition Corp. Class A Ordinary Shares was a new Davidson Kempner Partners position in Q1 2023.
  • BioPlus Acquisition Corp. Class A Ordinary Shares made up 0.05% of Davidson Kempner Partners's portfolio in Q1 2023, its #190 holding.
  • 61 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on Davidson Kempner Partners's 13F filing for Q1 2023, filed 15 May 2023.